AlTi Global Inc. trimmed its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 18.9% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,104 shares of the medical research company's stock after selling 1,423 shares during the quarter. AlTi Global Inc.'s holdings in Thermo Fisher Scientific were worth $3,041,000 at the end of the most recent reporting period.
Several other institutional investors have also added to or reduced their stakes in the stock. Amundi increased its stake in Thermo Fisher Scientific by 5.9% in the 1st quarter. Amundi now owns 3,029,044 shares of the medical research company's stock valued at $1,426,316,000 after buying an additional 168,197 shares during the last quarter. Aprio Wealth Management LLC increased its stake in Thermo Fisher Scientific by 52.7% in the 1st quarter. Aprio Wealth Management LLC now owns 1,561 shares of the medical research company's stock valued at $777,000 after buying an additional 539 shares during the last quarter. Federation des caisses Desjardins du Quebec increased its stake in Thermo Fisher Scientific by 4.7% in the 1st quarter. Federation des caisses Desjardins du Quebec now owns 76,001 shares of the medical research company's stock valued at $37,826,000 after buying an additional 3,415 shares during the last quarter. Unisphere Establishment increased its stake in shares of Thermo Fisher Scientific by 14.7% during the 1st quarter. Unisphere Establishment now owns 1,950,000 shares of the medical research company's stock worth $970,320,000 after purchasing an additional 250,000 shares during the last quarter. Finally, EP Wealth Advisors LLC increased its stake in shares of Thermo Fisher Scientific by 10.7% during the 1st quarter. EP Wealth Advisors LLC now owns 17,562 shares of the medical research company's stock worth $8,739,000 after purchasing an additional 1,704 shares during the last quarter. 89.23% of the stock is owned by institutional investors.
Wall Street Analyst Weigh In
A number of research analysts recently commented on the stock. Raymond James Financial reiterated an "outperform" rating and issued a $535.00 price target (up previously from $525.00) on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Wells Fargo & Company decreased their price target on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating on the stock in a research note on Thursday, July 24th. Robert W. Baird upped their price target on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an "outperform" rating in a research note on Thursday, July 24th. UBS Group boosted their price objective on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a "neutral" rating in a report on Thursday, July 24th. Finally, William Blair initiated coverage on shares of Thermo Fisher Scientific in a report on Monday, August 18th. They issued an "outperform" rating for the company. Sixteen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $593.00.
Check Out Our Latest Report on Thermo Fisher Scientific
Insider Transactions at Thermo Fisher Scientific
In related news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $500.96, for a total transaction of $5,009,600.00. Following the transaction, the chief executive officer directly owned 115,174 shares of the company's stock, valued at $57,697,567.04. This represents a 7.99% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Joseph R. Holmes sold 385 shares of the stock in a transaction on Friday, August 29th. The stock was sold at an average price of $492.63, for a total transaction of $189,662.55. Following the transaction, the chief accounting officer directly owned 2,319 shares in the company, valued at approximately $1,142,408.97. This represents a 14.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 29,666 shares of company stock worth $13,982,763 over the last three months. 0.33% of the stock is owned by company insiders.
Thermo Fisher Scientific Price Performance
Shares of NYSE:TMO opened at $486.82 on Wednesday. The company has a market cap of $183.83 billion, a price-to-earnings ratio of 28.16, a PEG ratio of 2.63 and a beta of 0.75. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. The firm has a 50 day simple moving average of $456.01 and a 200 day simple moving average of $453.73. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $627.88.
Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The firm had revenue of $10.86 billion during the quarter, compared to analysts' expectations of $10.68 billion. During the same period in the prior year, the company posted $5.37 EPS. The company's revenue was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.
Thermo Fisher Scientific Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be given a dividend of $0.43 per share. The ex-dividend date is Monday, September 15th. This represents a $1.72 annualized dividend and a dividend yield of 0.4%. Thermo Fisher Scientific's dividend payout ratio is 9.95%.
About Thermo Fisher Scientific
(
Free Report)
Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
See Also
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Thermo Fisher Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.
While Thermo Fisher Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
